Cortisol and hypothalamic-pituitary-gonadal axis hormones in follicular-phase women with fibromyalgia and chronic fatigue syndrome and effect of depressive symptoms on these hormones

Basit Öğe Kaydı
dc.contributor.authorGur, A
dc.contributor.authorCevik, R
dc.contributor.authorNas, K
dc.contributor.authorColpan, L
dc.contributor.authorSarac, S
dc.date.accessioned2024-04-24T17:14:53Z
dc.date.available2024-04-24T17:14:53Z
dc.date.issued2004
dc.departmentDicle Üniversitesien_US
dc.description.abstractWe investigated abnormalities of the hypothalamic-pituitary gonadal axis and cortisol concentrations in women with fibromyalgia and chronic fatigue syndrome (CFS) who were in the follicular phase of their menstrual cycle, and whether their scores for depressive symptoms were related to levels of these hormones. A total of 176 subjects participated-46 healthy volunteers, 68 patients with fibromyalgia, and 62 patients with CFS. We examined concentrations of follicle-stimulating hormone, luteinizing hormone (LH), estradiol, progesterone, prolactin, and cortisol. Depressive symptoms were assessed using the Beck Depression Inventory (BDI). Cortisol levels were significantly lower in patients with fibromyalgia or CFS than in healthy controls (P<0.05); there were no significant differences in other hormone levels between the three groups. Fibromyalgia patients with high BDI scores had significantly lower cortisol levels than controls (P<0.05), and so did CFS patients, regardless of their BDI scores (P<0.05). Among patients without depressive symptoms, cortisol levels were lower in CFS than in fibromyalgia (P<0.05). Our study suggests that in spite of low morning cortisol concentrations, the only abnormalities in hypothalamic-pituitary-gonadal axis hormones among follicular-phase women with fibromyalgia or CFS are those of LH levels in fibromyalgia patients with a low BDI score. Depression may lower cortisol and LH levels, or, alternatively, low morning cortisol may be a biological factor that contributes to depressive symptoms in fibromyalgia. These parameters therefore must be taken into account in future investigations.en_US
dc.identifier.doi10.1186/ar1163
dc.identifier.endpageR238en_US
dc.identifier.issn1478-6354
dc.identifier.issn1478-6362
dc.identifier.issue3en_US
dc.identifier.pmid15142269
dc.identifier.scopus2-s2.0-12344281899
dc.identifier.scopusqualityQ1
dc.identifier.startpageR232en_US
dc.identifier.urihttps://doi.org/10.1186/ar1163
dc.identifier.urihttps://hdl.handle.net/11468/18244
dc.identifier.volume6en_US
dc.identifier.wosWOS:000222512700013
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherBmcen_US
dc.relation.ispartofArthritis Research & Therapy
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectChronic Fatigue Syndromeen_US
dc.subjectCortisolen_US
dc.subjectDepressionen_US
dc.subjectFibromyalgiaen_US
dc.subjectHypothalamic-Pituitary-Gonadal Axisen_US
dc.titleCortisol and hypothalamic-pituitary-gonadal axis hormones in follicular-phase women with fibromyalgia and chronic fatigue syndrome and effect of depressive symptoms on these hormonesen_US
dc.titleCortisol and hypothalamic-pituitary-gonadal axis hormones in follicular-phase women with fibromyalgia and chronic fatigue syndrome and effect of depressive symptoms on these hormones
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu